查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1827771

2025年照护现场分子诊断全球市场报告

Point-Of-Care Molecular Diagnostics Global Market Report 2025
出版日期: | 出版商: The Business Research Company | 英文 250 Pages | 商品交期: 2-10个工作天内

价格
简介目录

近年来，照护现场分子诊断市场规模迅速扩张，从2024年的35.5亿美元成长至2025年的39.8亿美元，复合年增长率为12.0%。预测期内的成长可归因于快速疾病诊断需求的不断增长、感染疾病的不断增加、远端医疗和远距检测的扩展、照护现场的监管支持以及对个人化和精准医疗的需求。

预计未来几年照护现场分子诊断市场将快速成长，到2029年将达到69.2亿美元，复合年增长率为14.8%。预测期内的增长可归因于诊断设备的小型化、癌症和遗传疾病即时检测的扩展、面向各种应用的定制分子诊断、人工智能和机器学习在数据分析中的集成以及新兴感染疾病的监测。预测期内的主要趋势包括实验室晶片和微流体技术、数位健康和​​基于智慧型手机的诊断、照护现场COVID-19和疫情应对措施、人工智慧主导的预测性诊断以及基于Crisp®的分子检测。

即时诊断 (POC) 分子诊断旨在检测临床检体（例如粪便、唾液、尿液、血液和组织）中的特定核酸。这些诊断方法依赖于识别微生物遗传物质的目标片段，特别是 DNA 或 RNA。 POC 分子诊断广泛应用于医疗保健领域，已获得紧急使用授权 (EUA)，可用于诊断多种疾病。这些诊断方法可用于检测人体样本中的疾病抗原和抗体，包括单核球增多症、流感和 A 型链球菌(GAS) 的抗原和抗体。

照护现场分子诊断领域的关键产品和服务包括检测试剂套件、仪器和分析仪以及软体和服务。检测试剂套件是用于进行分析的仪器，特别适用于疾病通路研究。它们常用于快速且准确地诊断和监测各种疾病。即时分子诊断采用逆转录聚合酵素链锁反应(RT-PCR)、原位杂合反应和定序等技术来诊断呼吸系统疾病、医院获得性感染 (HAI)、癌症/肿瘤、肝炎和血液疾病等疾病。照护现场分子诊断广泛应用于医疗机构，例如分散式实验室、医院、居家照护和辅助生活机构。

2025年春季美国关税的突然上调及其引发的贸易摩擦对医疗设备行业产生了重大影响，尤其对用于诊断影像设备的进口零件、手术用不銹钢和一次性塑胶製品产生了重大影响。由于医院和诊所抵制涨价，製造商面临利润压力。监管挑战使情况更加复杂，因为由于关税而更换供应商通常需要医疗设备重新认证，导致市场进入延迟。为此，企业正在透过双重采购关键零件、增加标准化产品的国内生产以及加快寻找更具成本效益的材料来降低风险。

本研究报告是商业研究公司 (The Business Research Company) 新报告系列的一部分，该系列提供照护现场诊断市场统计数据，包括全球市场规模、区域份额、竞争对手的照护现场诊断市场份额、照护现场照护现场诊断的详细细分市场、市场趋势和商机，以及您在照护现场诊断行业取得成功所需的数据。照护现场分子诊断市场研究报告对该行业的现状和未来趋势进行了详细分析，为您提供所需的一切观点。

未来五年14.8%的预测成长率比我们先前对该市场的预测略有下降0.2个百分点。这一下降主要源自于美国与其他国家之间关税的影响。这种影响可能会直接影响美国，透过提高进口恆温扩增酶和微晶片阵列（主要来自英国和以色列）的关税，从而提高携带式传染病检查的成本。由于互惠关税以及不断升级的贸易摩擦和贸易限制对全球经济和贸易的负面影响，这种影响也将更加广泛。

感染疾病和呼吸道疾病盛行率的大幅上升预计将成为照护现场分子诊断市场成长的主要驱动力。引起呼吸道感染疾病的微生物，无论是病毒或细菌，都会透过咳嗽、打喷嚏和直接接触等多种方式传播。这些疾病的严重性需要各种治疗方法，包括吸入药物、口服药物、静脉注射疗法和照护现场诊断，以有效地患者照护。例如，根据英国国家统计局的数据，35 至 69 岁人群和 12 至 24 岁的学龄儿童的感染率有所上升，这凸显了对有效的照护现场诊断以应对感染疾病和呼吸道疾病的迫切需求。

人们对心臟衰竭治疗的认识不断提高，推动了照护现场(POC) 分子诊断市场的成长。心臟衰竭是一种影响心臟有效泵血能力的疾病，POC 分子诊断可以透过提供快速且准确的诊断，实现早期疗育并改善患者预后，从而带来显着优势。根据美国心臟协会的报告，心臟衰竭诊断数量呈上升趋势，预计到 2030 年将增加 46%，达到 800 多万心臟衰竭患者。在印度，农村和都市区的冠状动脉疾病发生率都在迅速增加。人们对心臟衰竭治疗的认识不断提高，凸显了 POC 分子诊断在这一医疗领域可以发挥的重要作用。

推动照护现场的关键趋势是技术创新。主要市场参与企业正致力于提供先进的解决方案，以巩固其市场地位。各公司正将酵素结合免疫吸附检测法(ELISA)、聚合酵素链锁反应(PCR)、质谱 (MS)、原位杂合反应、频谱核型分析成像和 DNA 微阵列等新一代技术融入其即时分子诊断 (POC) 设备，以缩短分析时间并降低成本。例如，Sensible Diagnostics 推出了一款可在 10 分钟内提供结果的即时分子诊断系统，展现了其在快速提供结果方面的技术进步。

照护现场（POC）分子诊断市场的主要参与者正在积极建立策略伙伴关係关係，以推出基于 CRISPR 的即时诊断检测。例如，CrisprBits 已与 MolBio Diagnostics 合作，利用其生物技术专业知识以及翻译、生产和分销能力，开髮用于检测病原体和基因标记的即时诊断检测。

2024年7月，总部位于瑞士、专注于药物、治疗方法和诊断开发的全球医疗保健公司罗氏控股有限公司（Roche Holding AG）收购了Lumiradex Ltd.，收购金额未披露。此次收购旨在增强罗氏控股有限公司的诊断产品组合，改善分散式医疗保健解决方案的可近性，并提升检测能力，尤其是在医疗资源匮乏的地区。 LumiraDx Ltd.是一家总部位于英国的诊断公司，专注于开发创新的照护现场（POC）检测解决方案。

在照护现场分子诊断市场运作的主要企业包括雅培实验室、罗氏公司、生物梅里埃公司、丹纳赫公司、Quidel 公司、生物梅里埃公司、Bio-Rad Laboratories Inc.、Sysmex 公司、Illumina 公司、Myriad Genetics Inc.、西门子医疗有限公司、Almacator 公司、Illumina 公司、Myriad Genetics Inc.、西门子医疗有限公司、Almacator 集团、Biogenpication Inc. Inc.、Genomic Health Inc、Grail、Hologic、HTG Molecular Diagnostics、Inivata、Invivoscribe、MolecularMD、Natera、NeoGenomics Laboratories、Personal Genome Diagnostics、Prometheus Laboratories、Ventana Medical Systems、Vermillion、Guardal Genome Diagnostics、Prometheus Laboratories、Ventana Medical Systems、Vermillion、Guardant Health、Exact Sciences 和 Biocartis Group。 NV、ArcherDx、Bio-Techne、AccuBiotech Co.Ltd.、Becton, Dickinson and Company、Chembio Diagnostics Inc.、Credo Diagnostics Biomedical Pvt. Ltd.、EKF Diagnostics、GenePOC Inc.

2024年，北美是照护现场分子诊断市场最大的地区。预计亚太地区将成为预测期内成长最快的地区。照护现场分子诊断市场分析报告涵盖亚太地区、西欧、中欧和东欧、北美、南美以及中东和非洲。

照护现场分子诊断市场分析报告涵盖的国家有澳洲、巴西、中国、法国、德国、印度、印尼、日本、俄罗斯、韩国、英国和美国。

照护现场(POC) 分子诊断市场包括 AAT、抗原和抗体检测的收益。市场价值包括服务供应商销售或包含在其服务产品中的相关商品的价值。仅包括企业之间交易或销售给最终消费者的商品和服务。

目录

第一章执行摘要

第二章 市场特征

第三章 市场趋势与策略

第四章 市场：宏观经济情景，包括利率、通膨、地缘政治、贸易战和关税，以及新冠疫情和復苏对市场的影响

第五章 全球成长分析与策略分析框架

  • 全球照护现场分子诊断：PESTEL 分析（政治、社会、技术、环境、法律因素、驱动因素与限制因素）
  • 最终用途产业分析
  • 全球照护现场分子诊断市场：成长率分析
  • 全球照护现场分子诊断市场表现：规模与成长，2019-2024
  • 全球照护现场分子诊断市场预测：规模与成长，2024-2029 年，2034 年预测
  • 全球照护现场分子诊断：总潜在市场（TAM）

第六章 市场细分

  • 全球照护现场诊断分子诊断市场（依产品及服务、绩效及预测）2019-2024 年、2024-2029 年、2034 年
  • 检测方法和套件
  • 仪器和分析设备
  • 软体和服务
  • 全球照护现场分子诊断市场：依技术、绩效及预测，2019-2024 年、2024-2029 年、2034 年
  • 逆转录聚合酵素链锁反应（RT-PCR）
  • 原位杂交
  • 定序
  • 全球照护现场分子诊断市场：依应用、绩效及预测，2019-2024 年、2024-2029 年、2034 年
  • 呼吸系统疾病
  • 院内感染（HAI）
  • 癌症/肿瘤学
  • 肝炎
  • 血液学
  • 全球照护现场分子诊断市场：按最终用户、实际和预测，2019-2024 年、2024-2029 年、2034 年
  • 分散式实验室
  • 医院
  • 居家护理
  • 辅助医疗设施
  • 全球照护现场分子诊断市场：依检测及套件类型细分，实际及预测，2019-2024 年、2024-2029 年、2034 年
  • 核酸增幅检查（NAAT）
  • 快速诊断测试
  • 分子检测试剂套件
  • 试剂和耗材
  • 全球照护现场分子诊断市场：按仪器和分析设备（按类型）细分，实际和预测，2019-2024 年、2024-2029 年、2034 年
  • PCR仪
  • 微流体设备
  • 序列器
  • 照护现场分析仪
  • 全球照护现场分子诊断市场：依软体及服务细分（按类型）、绩效及预测，2019-2024 年、2024-2029 年、2034 年
  • 资料管理软体
  • 云端基础的解决方案
  • 技术支援和维护服务
  • 咨询和培训服务

第七章 区域和国家分析

  • 全球照护现场分子诊断市场：区域表现及预测（2019-2024 年、2024-2029 年及 2034 年）
  • 全球照护现场分子诊断市场：依国家/地区、绩效及预测，2019-2024 年、2024-2029 年、2034 年

第八章 亚太市场

第九章：中国市场

第十章 印度市场

第十一章 日本市场

第十二章：澳洲市场

第十三章 印尼市场

第十四章 韩国市场

第十五章：西欧市场

第十六章英国市场

第十七章：德国市场

第18章：法国市场

第十九章：义大利市场

第20章：西班牙市场

第21章 东欧市场

第22章：俄罗斯市场

第23章 北美市场

第24章美国市场

第25章：加拿大市场

第26章 南美洲市场

第27章：巴西市场

第28章 中东市场

第29章：非洲市场

第30章：竞争格局与公司概况

  • 照护现场分子诊断市场：竞争格局
  • 照护现场分子诊断市场：公司简介
    • Abbott Laboratories Overview, Products and Services, Strategy and Financial Analysis
    • F Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
    • BioMerieux SA Overview, Products and Services, Strategy and Financial Analysis
    • Danaher Corporation Overview, Products and Services, Strategy and Financial Analysis
    • Quidel Corporation Overview, Products and Services, Strategy and Financial Analysis

第31章：其他领先和创新企业

  • BioMerieux SA
  • Bio-Rad Laboratories Inc.
  • Sysmex Corporation
  • Illumina Inc.
  • Myriad Genetics Inc.
  • Siemens Healthcare GmbH
  • Almac Group
  • Biogenex Laboratories Inc.
  • Cepheid Inc.
  • Epic Sciences Inc.
  • Foundation Medicine Inc.
  • Genomic Health Inc.
  • Grail Inc.
  • Hologic Inc.
  • HTG Molecular Diagnostics Inc.

第 32 章全球市场竞争基准化分析与仪表板

第33章 重大併购

第34章近期市场趋势

第 35 章：高潜力市场国家、细分市场与策略

  • 2029 年照护现场诊断分子诊断市场：提供新机会的国家
  • 2029 年照护现场诊断分子诊断市场：细分市场将带来新机会
  • 2029 年照护现场诊断分子诊断市场：成长策略
    • 基于市场趋势的策略
    • 竞争对手策略

第36章 附录

简介目录
Product Code: r21949u

Point-of-care (POC) molecular diagnostics are tests designed to detect specific nucleic acids in clinical specimens, including feces, saliva, urine, blood, and tissue. These diagnostics rely on identifying targeted portions of microbial genetic material, specifically DNA or RNA. Widely utilized in the healthcare sector, POC molecular diagnostics are granted emergency usage authorization to diagnose various diseases. These diagnostics are instrumental in detecting disease antigens or antibodies in human samples, such as mononucleosis, influenza, and group A streptococcus (GAS).

The primary products and services in point-of-care molecular diagnostics include assays and kits, instruments and analyzers, and software and services. Assays and kits are equipment used to carry out analyses, especially in studying disease pathways. They are commonly employed for rapid and accurate diagnosis and monitoring of various diseases. Technologies such as reverse transcription-polymerase chain reaction (RT-PCR), in situ hybridization, and sequencing are utilized in POC molecular diagnostics for diagnosing diseases like respiratory diseases, hospital-acquired infections (HAIs), cancer/oncology, hepatitis, and hematology. Point-of-care molecular diagnostics are employed in decentralized labs, hospitals, home care, and assisted living healthcare facilities.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp increase in U.S. tariffs and resulting trade tensions in spring 2025 are significantly impacting the medical equipment sector, especially for imported components used in imaging machines, surgical-grade stainless steel, and disposable plastics. With hospitals and clinics pushing back against price increases, manufacturers are facing margin pressure. The situation is further complicated by regulatory challenges, as switching suppliers due to tariffs often necessitates re-certification of medical devices, leading to delays in market entry. In response, companies are mitigating risks by dual-sourcing key components, ramping up domestic production of standardized items, and accelerating research into more cost-effective materials.

The point-of-care molecular diagnostics market research report is one of a series of new reports from The Business Research Company that provides point-of-care molecular diagnostics market statistics, including point-of-care molecular diagnostics industry global market size, regional shares, competitors with a point-of-care molecular diagnostics market share, detailed point-of-care molecular diagnostics market segments, market trends and opportunities, and any further data you may need to thrive in the point-of-care molecular diagnostics industry. This point-of-care molecular diagnostics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The point-of-care molecular diagnostics market size has grown rapidly in recent years. It will grow from $3.55 billion in 2024 to $3.98 billion in 2025 at a compound annual growth rate (CAGR) of 12.0%. The growth in the historic period can be attributed to increasing demand for rapid disease diagnosis, growth in infectious disease outbreaks, expansion of telemedicine and remote testing, regulatory support for point-of-care diagnostics, need for personalized and precision medicine.

The point-of-care molecular diagnostics market size is expected to see rapid growth in the next few years. It will grow to $6.92 billion in 2029 at a compound annual growth rate (CAGR) of 14.8%. The growth in the forecast period can be attributed to miniaturization of diagnostic devices, expansion of poc testing for cancer and genetic diseases, customized molecular diagnostics for diverse applications, integration of ai and machine learning for data analysis, emerging infectious disease surveillance. Major trends in the forecast period include lab-on-a-chip and microfluidic technologies, digital health and smartphone-based diagnostics, point-of-care covid-19 and pandemic preparedness, ai-driven predictive diagnostics, crispr-based molecular testing.

The forecast of 14.8% growth over the next five years indicates a slight reduction of 0.2% from the previous estimate for this market.This reduction is primarily due to the impact of tariffs between the US and other countries. This is likely to directly affect the US through increased tariffs on isothermal amplification enzymes and microchip arrays, mainly imported from the UK and Israel, raising costs for portable infectious disease testing.The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The significant rise in the prevalence of infectious and respiratory diseases is anticipated to be a major driver for the growth of the point-of-care molecular diagnostics market. Microorganisms causing respiratory infections, whether viral or bacterial, can spread through various means, including coughing, sneezing, or direct contact. The severity of these diseases necessitates a range of treatments, including inhalers, oral medications, intravenous treatments, and point-of-care molecular diagnostics for effective patient care. For example, in England, according to the Office for National Statistics, the infection rate increased among individuals aged 35 to 69 and those in school years 12 to 24, highlighting the urgency for effective point-of-care molecular diagnostics to address infectious and respiratory diseases.

The increasing awareness regarding heart failure treatment is poised to propel the growth of the point-of-care (POC) molecular diagnostics market. Heart failure, a condition impacting the heart's ability to pump blood effectively, can benefit significantly from POC molecular diagnostics, offering swift and accurate diagnoses for early interventions and improved patient outcomes. The American Heart Association reports a rising number of heart failure diagnoses, projected to increase by 46% by 2030, exceeding 8 million people with heart failure. In India, coronary incidences have surged in both rural and urban populations. This growing awareness about heart failure treatment underscores the potential for POC molecular diagnostics to play a crucial role in this medical domain.

A key trend gaining traction in the point-of-care molecular diagnostics market is technological innovation. Major market players are dedicated to providing advanced solutions to strengthen their market positions. Companies are incorporating next-generation technologies such as enzyme-linked immunosorbent assay (ELISA), polymerase chain reaction (PCR), mass spectrometry (MS), situ hybridizations, spectral karyotyping imaging, DNA microarrays, etc., on POC devices, accelerating analysis times and reducing costs. For instance, Sensible Diagnostics introduced a 10-minute point-of-care PCR system, showcasing technological advancements to provide rapid results.

Strategic partnerships are being embraced by major players in the point-of-care molecular diagnostics market to launch POC CRISPR-based tests. For instance, CrisprBits collaborated with MolBio Diagnostics to leverage biotechnology expertise and translation, manufacturing, and distribution capabilities for developing POC tests detecting pathogens and genetic markers.

In July 2024, Roche Holding AG, a Switzerland-based global healthcare company focused on developing medicines, treatments, and diagnostics, acquired LumiraDx Ltd. for an undisclosed amount. This acquisition is intended to enhance Roche Holding AG's diagnostics portfolio, improve access to decentralized healthcare solutions, and expand testing capabilities, especially in underserved regions. LumiraDx Ltd. is a UK-based diagnostic company that specializes in creating innovative point-of-care (POC) testing solutions.

Major companies operating in the point-of-care molecular diagnostics market include Abbott Laboratories, F Hoffmann-La Roche Ltd., BioMerieux SA, Danaher Corporation, Quidel Corporation, BioMerieux SA, Bio-Rad Laboratories Inc., Sysmex Corporation, Illumina Inc., Myriad Genetics Inc., Siemens Healthcare GmbH, Almac Group, Biogenex Laboratories Inc., Cepheid Inc., Epic Sciences Inc., Foundation Medicine Inc., Genomic Health Inc., Grail Inc., Hologic Inc., HTG Molecular Diagnostics Inc., Inivata Ltd., Invivoscribe Inc., MolecularMD Corporation, Natera Inc., NeoGenomics Laboratories Inc., Personal Genome Diagnostics Inc., Prometheus Laboratories Inc., Ventana Medical Systems Inc., Vermillion Inc., Guardant Health Inc., Exact Sciences Corporation, Biocartis Group NV, ArcherDx Inc., Bio-Techne Corporation, AccuBiotech Co. Ltd., Becton, Dickinson and Company, Chembio Diagnostics Inc., Credo Diagnostics Biomedical Pvt. Ltd., EKF Diagnostics, GenePOC Inc.

North America was the largest region in the point-of-care molecular diagnostics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the point-of-care molecular diagnostics market analysis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.

The countries covered in the point-of-care molecular diagnostics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK and USA.

The point-of-care (POC) molecular diagnostics market includes revenues earned by AAT, antigen, or antibody tests. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Point-Of-Care Molecular Diagnostics Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on point-of-care molecular diagnostics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
  • Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for point-of-care molecular diagnostics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The point-of-care molecular diagnostics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

  • Markets Covered:1) By Product And Service: Assays And Kits; Instruments And Analyzers; Software And Services
  • 2) By Technology: Reverse Transcription - Polymerase Chain Reaction (RT-PCR); In Situ Hybridization; Sequencing
  • 3) By Application: Respiratory Diseases; Hospital Acquired Infections (HAIs); Cancer/Oncology; Hepatitis; Hematology
  • 4) By End-User: Decentralized Labs; Hospitals; Home Care; Assisted Living Healthcare Facilities
  • Subsegments:
  • 1) By Assays And Kits: Nucleic Acid Amplification Tests (NAATs); Rapid Diagnostic Tests; Molecular Detection Kits; Reagents And Consumables
  • 2) By Instruments And Analyzers: PCR Machines; Microfluidic Devices; Sequencers; Point-of-Care Analyzers
  • 3) By Software And Services: Data Management Software; Cloud-Based Solutions; Technical Support And Maintenance Services; Consultation And Training Services
  • Companies Mentioned: Abbott Laboratories; F Hoffmann-La Roche Ltd.; BioMerieux SA; Danaher Corporation; Quidel Corporation; BioMerieux SA; Bio-Rad Laboratories Inc.; Sysmex Corporation; Illumina Inc.; Myriad Genetics Inc.; Siemens Healthcare GmbH; Almac Group; Biogenex Laboratories Inc.; Cepheid Inc.; Epic Sciences Inc.; Foundation Medicine Inc.; Genomic Health Inc.; Grail Inc.; Hologic Inc.; HTG Molecular Diagnostics Inc.; Inivata Ltd.; Invivoscribe Inc.; MolecularMD Corporation; Natera Inc.; NeoGenomics Laboratories Inc.; Personal Genome Diagnostics Inc.; Prometheus Laboratories Inc.; Ventana Medical Systems Inc.; Vermillion Inc.; Guardant Health Inc.; Exact Sciences Corporation; Biocartis Group NV; ArcherDx Inc.; Bio-Techne Corporation; AccuBiotech Co. Ltd.; Becton, Dickinson and Company; Chembio Diagnostics Inc.; Credo Diagnostics Biomedical Pvt. Ltd.; EKF Diagnostics; GenePOC Inc.
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time Series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Point-Of-Care Molecular Diagnostics Market Characteristics

3. Point-Of-Care Molecular Diagnostics Market Trends And Strategies

4. Point-Of-Care Molecular Diagnostics Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

  • 4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Point-Of-Care Molecular Diagnostics Growth Analysis And Strategic Analysis Framework

  • 5.1. Global Point-Of-Care Molecular Diagnostics PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
  • 5.2. Analysis Of End Use Industries
  • 5.3. Global Point-Of-Care Molecular Diagnostics Market Growth Rate Analysis
  • 5.4. Global Point-Of-Care Molecular Diagnostics Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
  • 5.5. Global Point-Of-Care Molecular Diagnostics Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
  • 5.6. Global Point-Of-Care Molecular Diagnostics Total Addressable Market (TAM)

6. Point-Of-Care Molecular Diagnostics Market Segmentation

  • 6.1. Global Point-Of-Care Molecular Diagnostics Market, Segmentation By Product And Service, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Assays And Kits
  • Instruments And Analyzers
  • Software And Services
  • 6.2. Global Point-Of-Care Molecular Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Reverse Transcription - Polymerase Chain Reaction (RT-PCR)
  • In Situ Hybridization
  • Sequencing
  • 6.3. Global Point-Of-Care Molecular Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Respiratory Diseases
  • Hospital Acquired Infections (HAIs)
  • Cancer/Oncology
  • Hepatitis
  • Hematology
  • 6.4. Global Point-Of-Care Molecular Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Decentralized Labs
  • Hospitals
  • Home Care
  • Assisted Living Healthcare Facilities
  • 6.5. Global Point-Of-Care Molecular Diagnostics Market, Sub-Segmentation Of Assays And Kits, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Nucleic Acid Amplification Tests (NAATs)
  • Rapid Diagnostic Tests
  • Molecular Detection Kits
  • Reagents And Consumables
  • 6.6. Global Point-Of-Care Molecular Diagnostics Market, Sub-Segmentation Of Instruments And Analyzers, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • PCR Machines
  • Microfluidic Devices
  • Sequencers
  • Point-of-Care Analyzers
  • 6.7. Global Point-Of-Care Molecular Diagnostics Market, Sub-Segmentation Of Software And Services, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Data Management Software
  • Cloud-Based Solutions
  • Technical Support And Maintenance Services
  • Consultation And Training Services

7. Point-Of-Care Molecular Diagnostics Market Regional And Country Analysis

  • 7.1. Global Point-Of-Care Molecular Diagnostics Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 7.2. Global Point-Of-Care Molecular Diagnostics Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Point-Of-Care Molecular Diagnostics Market

  • 8.1. Asia-Pacific Point-Of-Care Molecular Diagnostics Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Point-Of-Care Molecular Diagnostics Market, Segmentation By Product And Service, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.3. Asia-Pacific Point-Of-Care Molecular Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.4. Asia-Pacific Point-Of-Care Molecular Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Point-Of-Care Molecular Diagnostics Market

  • 9.1. China Point-Of-Care Molecular Diagnostics Market Overview
  • 9.2. China Point-Of-Care Molecular Diagnostics Market, Segmentation By Product And Service, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.3. China Point-Of-Care Molecular Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.4. China Point-Of-Care Molecular Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Point-Of-Care Molecular Diagnostics Market

  • 10.1. India Point-Of-Care Molecular Diagnostics Market, Segmentation By Product And Service, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.2. India Point-Of-Care Molecular Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.3. India Point-Of-Care Molecular Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Point-Of-Care Molecular Diagnostics Market

  • 11.1. Japan Point-Of-Care Molecular Diagnostics Market Overview
  • 11.2. Japan Point-Of-Care Molecular Diagnostics Market, Segmentation By Product And Service, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.3. Japan Point-Of-Care Molecular Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.4. Japan Point-Of-Care Molecular Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Point-Of-Care Molecular Diagnostics Market

  • 12.1. Australia Point-Of-Care Molecular Diagnostics Market, Segmentation By Product And Service, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.2. Australia Point-Of-Care Molecular Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.3. Australia Point-Of-Care Molecular Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Point-Of-Care Molecular Diagnostics Market

  • 13.1. Indonesia Point-Of-Care Molecular Diagnostics Market, Segmentation By Product And Service, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.2. Indonesia Point-Of-Care Molecular Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.3. Indonesia Point-Of-Care Molecular Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Point-Of-Care Molecular Diagnostics Market

  • 14.1. South Korea Point-Of-Care Molecular Diagnostics Market Overview
  • 14.2. South Korea Point-Of-Care Molecular Diagnostics Market, Segmentation By Product And Service, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.3. South Korea Point-Of-Care Molecular Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.4. South Korea Point-Of-Care Molecular Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Point-Of-Care Molecular Diagnostics Market

  • 15.1. Western Europe Point-Of-Care Molecular Diagnostics Market Overview
  • 15.2. Western Europe Point-Of-Care Molecular Diagnostics Market, Segmentation By Product And Service, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.3. Western Europe Point-Of-Care Molecular Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.4. Western Europe Point-Of-Care Molecular Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Point-Of-Care Molecular Diagnostics Market

  • 16.1. UK Point-Of-Care Molecular Diagnostics Market, Segmentation By Product And Service, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.2. UK Point-Of-Care Molecular Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.3. UK Point-Of-Care Molecular Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Point-Of-Care Molecular Diagnostics Market

  • 17.1. Germany Point-Of-Care Molecular Diagnostics Market, Segmentation By Product And Service, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.2. Germany Point-Of-Care Molecular Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.3. Germany Point-Of-Care Molecular Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Point-Of-Care Molecular Diagnostics Market

  • 18.1. France Point-Of-Care Molecular Diagnostics Market, Segmentation By Product And Service, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.2. France Point-Of-Care Molecular Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.3. France Point-Of-Care Molecular Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Point-Of-Care Molecular Diagnostics Market

  • 19.1. Italy Point-Of-Care Molecular Diagnostics Market, Segmentation By Product And Service, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.2. Italy Point-Of-Care Molecular Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.3. Italy Point-Of-Care Molecular Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Point-Of-Care Molecular Diagnostics Market

  • 20.1. Spain Point-Of-Care Molecular Diagnostics Market, Segmentation By Product And Service, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.2. Spain Point-Of-Care Molecular Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.3. Spain Point-Of-Care Molecular Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Point-Of-Care Molecular Diagnostics Market

  • 21.1. Eastern Europe Point-Of-Care Molecular Diagnostics Market Overview
  • 21.2. Eastern Europe Point-Of-Care Molecular Diagnostics Market, Segmentation By Product And Service, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.3. Eastern Europe Point-Of-Care Molecular Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.4. Eastern Europe Point-Of-Care Molecular Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Point-Of-Care Molecular Diagnostics Market

  • 22.1. Russia Point-Of-Care Molecular Diagnostics Market, Segmentation By Product And Service, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.2. Russia Point-Of-Care Molecular Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.3. Russia Point-Of-Care Molecular Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Point-Of-Care Molecular Diagnostics Market

  • 23.1. North America Point-Of-Care Molecular Diagnostics Market Overview
  • 23.2. North America Point-Of-Care Molecular Diagnostics Market, Segmentation By Product And Service, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.3. North America Point-Of-Care Molecular Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.4. North America Point-Of-Care Molecular Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Point-Of-Care Molecular Diagnostics Market

  • 24.1. USA Point-Of-Care Molecular Diagnostics Market Overview
  • 24.2. USA Point-Of-Care Molecular Diagnostics Market, Segmentation By Product And Service, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.3. USA Point-Of-Care Molecular Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.4. USA Point-Of-Care Molecular Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Point-Of-Care Molecular Diagnostics Market

  • 25.1. Canada Point-Of-Care Molecular Diagnostics Market Overview
  • 25.2. Canada Point-Of-Care Molecular Diagnostics Market, Segmentation By Product And Service, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.3. Canada Point-Of-Care Molecular Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.4. Canada Point-Of-Care Molecular Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Point-Of-Care Molecular Diagnostics Market

  • 26.1. South America Point-Of-Care Molecular Diagnostics Market Overview
  • 26.2. South America Point-Of-Care Molecular Diagnostics Market, Segmentation By Product And Service, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.3. South America Point-Of-Care Molecular Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.4. South America Point-Of-Care Molecular Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Point-Of-Care Molecular Diagnostics Market

  • 27.1. Brazil Point-Of-Care Molecular Diagnostics Market, Segmentation By Product And Service, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.2. Brazil Point-Of-Care Molecular Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.3. Brazil Point-Of-Care Molecular Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Point-Of-Care Molecular Diagnostics Market

  • 28.1. Middle East Point-Of-Care Molecular Diagnostics Market Overview
  • 28.2. Middle East Point-Of-Care Molecular Diagnostics Market, Segmentation By Product And Service, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.3. Middle East Point-Of-Care Molecular Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.4. Middle East Point-Of-Care Molecular Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Point-Of-Care Molecular Diagnostics Market

  • 29.1. Africa Point-Of-Care Molecular Diagnostics Market Overview
  • 29.2. Africa Point-Of-Care Molecular Diagnostics Market, Segmentation By Product And Service, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.3. Africa Point-Of-Care Molecular Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.4. Africa Point-Of-Care Molecular Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Point-Of-Care Molecular Diagnostics Market Competitive Landscape And Company Profiles

  • 30.1. Point-Of-Care Molecular Diagnostics Market Competitive Landscape
  • 30.2. Point-Of-Care Molecular Diagnostics Market Company Profiles
    • 30.2.1. Abbott Laboratories Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.2. F Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.3. BioMerieux SA Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.4. Danaher Corporation Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.5. Quidel Corporation Overview, Products and Services, Strategy and Financial Analysis

31. Point-Of-Care Molecular Diagnostics Market Other Major And Innovative Companies

  • 31.1. BioMerieux SA
  • 31.2. Bio-Rad Laboratories Inc.
  • 31.3. Sysmex Corporation
  • 31.4. Illumina Inc.
  • 31.5. Myriad Genetics Inc.
  • 31.6. Siemens Healthcare GmbH
  • 31.7. Almac Group
  • 31.8. Biogenex Laboratories Inc.
  • 31.9. Cepheid Inc.
  • 31.10. Epic Sciences Inc.
  • 31.11. Foundation Medicine Inc.
  • 31.12. Genomic Health Inc.
  • 31.13. Grail Inc.
  • 31.14. Hologic Inc.
  • 31.15. HTG Molecular Diagnostics Inc.

32. Global Point-Of-Care Molecular Diagnostics Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Point-Of-Care Molecular Diagnostics Market

34. Recent Developments In The Point-Of-Care Molecular Diagnostics Market

35. Point-Of-Care Molecular Diagnostics Market High Potential Countries, Segments and Strategies

  • 35.1 Point-Of-Care Molecular Diagnostics Market In 2029 - Countries Offering Most New Opportunities
  • 35.2 Point-Of-Care Molecular Diagnostics Market In 2029 - Segments Offering Most New Opportunities
  • 35.3 Point-Of-Care Molecular Diagnostics Market In 2029 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer